MarketPulse

warrant coverage

2 articles
BenzingaBenzinga··Prnewswire

Brainstorm Cell Therapeutics Completes $2M February Fundraising Round

Brainstorm Cell Therapeutics raised $2M in February through private placement at $0.60/share. Funds support general operations, regulatory work, and Phase 3b trial preparations for ALS therapy NurOwn.
BCLIprivate placementcapital raise
BenzingaBenzinga··Prnewswire

Brainstorm Cell Raises $1M Through Private Placement Above Current Valuation

Brainstorm Cell raised $1M via private placement at $0.60/share, above market price. Funds support Phase 3b ALS therapy trials and regulatory efforts.
BCLIprivate placementstem cell therapy